Wednesday, August 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 9, 2026

Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica

View original at finance.yahoo.com
Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica AstuteAnalytica India Pvt…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Growth is fueled by the adoption of advanced analytics platforms, AI-driven modules, and cloud-based solutions that optimize drug discovery, clinical trials, pharmacovigilance, and precision medicine

    80% confidence

  • North America's leadership in life sciences analytics stems from strong research infrastructure, extensive clinical trials, and a concentration of top-tier academic institutions

    80% confidence

  • The global life sciences analytics market was valued at 11.10 billion in 2024 and is expected to reach US$ 23.17 billion by 2033, growing at a CAGR of 8.52% from 2025 to 2033

    80% confidence

  • Leading players such as Roche, Johnson & Johnson, AstraZeneca, and Merck are investing heavily in specialized analytics tools and dedicated data teams to accelerate real-time decision-making, improve patient stratification, and enhance treatment outcomes

    80% confidence

Data points we hold from this source

AstraZeneca AB · solution count9 cloud_solutions
Sanofi · dashboard count3 unified_dashboards
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Life Sciences Analytics Market Advances to US$ 23.17 Billion by 2033 on AI-Driven Drug Discovery and Cloud Platforms Says Astute Analytica — Source | Via News | ViaNews Market